Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724061 · ClinicalTrials.gov registry record · NA
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00724061: Clinical Trial NA study, sponsored by Northwestern University.
NCT00724061 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00724061, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of mycosis fungoides/Sezary syndrome. Ultraviolet light therapy uses a drug, such as psoralen, that is absorbed by cancer cells. The drug becomes active when it is exposed to ultraviolet light. When the drug is active, cancer cells are killed. Giving PEG-interferon alfa-2b together with ultraviolet light therapy may kill more cancer cell. PURPOSE: This is a pilot study of dose-escalating pegylated IFN-α-2b and PUVA or NB-UVB. The purpose is to study the side effects and best dose of PEG-interferon alfa-2b to be given together with ultraviolet light therapy in patients with stage IB, stage II, stage III, or stage IVA mycosis fungoides/Sezary syndrome (CTCL).
Primary Outcome
Adverse events are graded according to the National Cancer Institute's Common Toxicity Criteria (CTCAE) version 3.0. In general, grades are assigned as follows: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE A dose limiting toxicity (DLT) will be defined as any grade 3 or higher hematologic toxicity or any grade 4 non-hematologic toxicity.
Interventions
- BIOLOGICAL Pegylated interferon α-2b
- OTHER Psoralens with ultraviolet light A
- OTHER Narrowband-ultraviolet light B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | NA |
Why NCT00724061 stopped before completion
NCT00724061 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Pegylated interferon α-2b is the first listed.
NCT00724061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00724061 about?
NCT00724061 is a clinical study titled "Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL". RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of mycosis fungoides/Sezary syndrome. Ultraviolet light therapy uses a drug, such as psoralen, that is absorbed by cancer cells. The drug becomes active when it is exposed to ultraviolet light. When t...
What is the current status of trial NCT00724061?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00724061?
The interventions under investigation include: Pegylated interferon α-2b (BIOLOGICAL), Psoralens with ultraviolet light A (OTHER), Narrowband-ultraviolet light B (OTHER).
Who is sponsoring clinical trial NCT00724061?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00724061's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia